Ryan Maynard - Cara Therapeutics Chief Officer
| 69C Stock | EUR 4.84 0.00 0.00% |
Insider
Ryan Maynard is Chief Officer of Cara Therapeutics
| Age | 54 |
| Phone | 203 406 3700 |
| Web | https://www.caratherapeutics.com |
Cara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4516) %, meaning that it generated substantial loss on money invested by shareholders. Cara Therapeutics' management efficiency ratios could be used to measure how well Cara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cara Therapeutics has accumulated 4.99 M in total debt with debt to equity ratio (D/E) of 4.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Cara Therapeutics has a current ratio of 3.33, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cara Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cara Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cara Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cara to invest in growth at high rates of return. When we think about Cara Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Paul Sagan | Moderna | 59 | |
| Lars Jorgensen | Novo Nordisk AS | 57 | |
| Israel Ruiz | Moderna | 47 | |
| Paul McKenzie | CSL Limited | 57 | |
| Camilla Sylvest | Novo Nordisk AS | 51 | |
| Jorg Burzer | Mercedes Benz Group AG | 53 | |
| Stephen Berenson | Moderna | 58 | |
| Damian Esq | Vertex Pharmaceuticals Incorpor | 47 | |
| John Reynders | Moderna | N/A | |
| Shannon Klinger | Moderna | 52 | |
| Stephen MD | Moderna | 47 | |
| Sierk Poetting | BioNTech SE | 50 | |
| Martin Lange | Novo Nordisk AS | 53 | |
| Mike Tirozzi | Vertex Pharmaceuticals Incorpor | N/A | |
| Jens Holstein | BioNTech SE | 60 | |
| Kristen Ambrose | Vertex Pharmaceuticals Incorpor | 46 | |
| Jeffrey MD | Vertex Pharmaceuticals Incorpor | 67 | |
| Paul BA | CSL Limited | 66 | |
| Jemimah Brennan | CSL Limited | N/A | |
| Marcello Damiani | Moderna | 49 | |
| Ryan Richardson | BioNTech SE | 44 | |
Management Performance
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 |
Cara Therapeutics Leadership Team
Elected by the shareholders, the Cara Therapeutics' board of directors comprises two types of representatives: Cara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutics' management team and ensure that shareholders' interests are well served. Cara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joana Goncalves, Chief Medical Officer | ||
| Christopher Posner, Director | ||
| Beth Weinberg, VP QA | ||
| Eric Vandal, VP Commercial | ||
| Frdrique Menzaghi, Chief RD | ||
| Iris Francesconi, Chief Relations | ||
| Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary | ||
| Dr DSc, CoFounder Advisor | ||
| Ryan Maynard, Chief Officer |
Cara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Shares Owned By Insiders | 16.10 % | |||
| Shares Owned By Institutions | 65.69 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.